Docetaxel in the treatment of advanced non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 8, 2008, Pages 1207-1222

  Saloustros, Emmanouel ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Taxane

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; APOPTOSIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINDESINE; ANTINEOPLASTIC AGENT; TAXOID;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LACRIMATION; LEUKOPENIA; LOW DRUG DOSE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; OTOTOXICITY; OVERALL SURVIVAL; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN DISEASE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; AGED; ARTICLE; LUNG TUMOR;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; TAXOIDS;

EID: 54549111941     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.8.1207     Document Type: Review

References (120)

1. Ahmedin J, Siegel R, Ward E. Cancer statistics 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94(2), 153-156 (2001).
3. Ettinger DS, Cox JD, Ginsberg RJ et al. NCCN non-small cell lung cancer practice guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt.) 10(Suppl. 11), 81-111 (1996).
4. American Society of Clinical Oncology. Outcome of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J. Clin. Oncol. 14(2), 671-679 (1996).
5. Pazdur R, Kudelka AP, Kavanagh JJ et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat. Rev. 19(4), 351-386 (1993).
6. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J. Natl Cancer Inst. 83, 288-291 (1991).
7. Lavelle F, Bissery MC, Combeau C et al. Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol. 22(Suppl. 4), 3-16 (1995).
8. Hanauske A-R, Degen D, Hilsenbeck SG et al. Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3, 121-124 (1992).
9. Diaz JF, Andreu. JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32, 2747-2755 (1993).
10. Andreu JM, Diaz JF, Gil R et al. Solution structure of Taxotere-induced microtubules to 3 nm resolution. J. Biol. Chem. 269, 31785-31792 (1994).
11. Riou J-F, Petitgenet O, Combeau C et al. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel. (Taxol) in P388 cell line. Proc. Am. Assoc. Cancer Res. USA (1994) (Abstract 385).
12. Sawada N, Ishikava T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/ Taxotere in human cancer xenografts. Clin. Cancer Res. 4, 1013-1019 (1998).
13. Riou J-F, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Commun. 187, 164-170 (1992).
14. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57, 229-233 (1997).
15. Guidolin D, Vacca A, Nussdorfer GG. A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc. Res. 67(2), 117-124 (2004).
16. Grant DS, Williams TL, Zahaczewsky M. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104(1), 121-129 (2003).
17. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat. Rev. 29(5), 407-415 (2003).
18. Brooks TA, Minderman H, O'Loughlin KL. et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther. 11, 1195-1205 (2003).
19. Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162 (1976).
20. Ueda K, Cornwell M, Gottesman M et al. The mdr1 gene, responsible for multidrug resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun. 141, 956-962 (1986).
21. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-1202 (2000).
22. Ranganathan S, Benetatos CA, Colarusso PJ et al. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer 77, 562-566 (1998).
23. Van Amerongen R, Berns A. TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes Dev. 20, 1975-1981 (2006).
24. Extra JM, Rousseau F, Bruno I, Clavel M, Le Bail, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Treat. Rev. 53(5), 1037-1042 (1993).
25. Engels FK, Ten Tije AJ, Baker SD et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther. 75(5), 448-454 (2004).
26. Synold T, Newman E, Lenz H-J et al. Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD). Proc. Am. Soc. Clin. Oncol. 18, 168a (1999) (Abstract 643).
27. Fronk LC, Schellens JH, Planting AS et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J. Clin. Oncol. 15(3), 1071-1079 (1997).
28. Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin. Oncol. 15(2), 750-758 (1997).
29. Kunitoh H, Watanabe K, Onoshi T, Furuce K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J. Clin. Oncol. 14(5), 1649-1655 (1996).
30. Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer 70(2), 384-387 (1994).
31. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75(4), 968-972 (1995).
32. Latreille J, Gelmon KA, Hirsh V et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest. New Drugs 16(3), 2 65-270 (1998).
33. Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. 12(6), 1238-1244 (1994).
34. Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J. Clin. Oncol. 12(6), 1232-1237 (1994).
35. Roszkowski K, Pluzanska A. Krzakow&ki M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27(3), 145-157 (2000).
36. Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens. The TAX 320 Non-Small Cell Lung Cancer Study group. J. Clin. Oncol. 18(12), 2354-2362 (2000).
37. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000).
38. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized Phase III trial. Lung Cancer 43(2), 183-194 (2004).
39. Hanna N, Shepherd FA, Fossella FV et al Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597(2004).
40. Douillard J, Kim E, Hirsh V et al. Gefitinib (Iressa) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). J. Thorac. Oncol. 2, S305 (Abstract PRS-02) (2007).
41. Fidias S, Dakhil A, Lyss D et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival. 2007 ASCO Annual Meeting Proceedings Part I. J Clin. Oncol. 25(18 Suppl.) (2007) (Abstract LBA7516).
42. Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol 16(6), 2164-2168 (1998).
43. Schuette W, Nagel S, Blankenburg T et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J. Clin. Oncol. 23 (33), 8389-8395(2005).
44. Camps C, Massuti B, Jiménez A et al. Randomized Phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann. Oncol. 17(3), 467-472 (2006).
45. Di Maio M, Perrone F, Chodini P et al. Individual patient data meta-analysis of docetaxel. administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 25(11), 1377-1382 (2007).
46. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
47. Sweeney CJ, Zhu J, Sandier AB et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non small cell lung carcinoma. Cancer 92(10), 2639-2647 (2001).
48. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 23(33), 8389-8395 (2005).
49. Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer. the Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol. 22(2), 254-261 (2004).
50. Lee WS, Bae BJ, Ryon HM, Bae SH, Lee SC, Hyun DS. Efficacy of weekly docetaxel combined with platinum as first line treatment in patients with advanced non-small cell lung cancer. Eur. J. Cancer Suppl. 5(4), 393 (2007).
51. Booton R, Lorigan P, Anderson H et al. A Phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann. Oncol. 17(7), 1111-1119 (2006).
52. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J. Clin. Oncol. 23(33), 8389-8395 (2005).
53. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-fine treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl Cancer Inst. 99(11), 847-857 (2007).
54. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus nonplatinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59(1), 1-11 (2008).
55. Georgoulias V, Ardavanis A, Aggelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter Phase III trial. J. Clin. Oncol. 22(13), 2602-2609 (2004).
56. Groen H, Schramel FM, Van der Hoeven JJM et al. Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC). An interim analysis of a multicenter Phase III trial. Proc. Am. Soc. Clin. Oncol. 22, 623 (2003) (Abstract 2505).
57. Georgolias V, Androulakis N, Kotsakis A et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter Pbase III trial. Lung Cancer 59(1), 57-63 (2008).
58. Georgoulias V, Ardavanis A, Aggelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter Phase III trial. J. Clin. Oncol. 22(13), 2602-2609 (2004).
59. Popa IE, Stewart K, Smith FP, Rizvi NA. A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer 95(8), 1714-1719 (2002).
60. Israel V, Tagawa ST, Snyder T, Jeffers S, Raghavan D. Phase I/H trial of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC). Invest. New Drugs 22(3), 291-297 (2004).
61. Rocha Lima CM, Rizvi NA, Zhang C et al. Randomized Phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann. Oncol. 15(3), 410-418 (2004).
62. Georgoulias V, Ardvanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol. 23(13), 2937-2945 (2005).
63. Ziotopoulos P, Androulakis N, Mylonaki E et al. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre Phase II study. Lung Cancer 50(1), 115-122 (2005).
64. Page RD, Smith FP, Geils GF et al. Prospective multi-center Phase II trial of docetaxel and vinorelbine with filgrastim support in subjects with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22(Suppl. 14), 650S (2004) (Abstract 7138).
65. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J. Clin. Oncol. 22(22), 330-353 (2004).
66. Georgoulias V, Papadakis E. Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357(9267), 1478-1484 (2001).
67. Rigas J, Dragnev K, Kerry M et al. Survival equivalence of non-platinum based and platinum based chemotherapy for advanced non-small cell lung cancer (NSCLC): the results of a multicenter internet-based Phase III randomized study. Lung Cancer 49(Suppl. 2), S35 (2005) (Abstract 0-098).
68. D'Addario G, Pintilie M, Leithl NB et al. Platinum-based versus non-platinum-based chemotherapy in advanced non small-cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. 23(13), 2926-2936 (2005).
69. Niho S, Kubota K, Goto K et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a Phase I/II trial. Cancer Chemother. Pharmacol. 52(1), 19-24 (2003).
70. Takeda K, Negoro S, Tamura T et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): results of a JCOG randomized trial (JCOG0104). J. Clin. Oncol. 22(Suppl. 14), 625s (2004).
71. Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients falling previous chemotherapy. Am. J. Clin. Oncol. 25(5), 509-512 (2002).
72. Kouroussis C, Mavroudis D, Kakolyris S et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44(3), 363-368 (2004).
73. Langer CJ, Vancel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCLC do as well as younger PTS (<70 years). Proc. Am. Soc. Clin. Oncol. 22, 639 (2003) (Abstract 2571).
74. Lilenbaum RC, Herndon IE, List M et al. Single agent versus combination chemotherapy in patients with advanced non small ceil lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. J. Clin. Obcol. 23(1), 190-196 (2005).
75. No authors listed. Effects of vinorelbine on quality of fife and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl Cancer Inst. 91, 66-72 (1999).
76. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl Cancer Inst. 95, 362-372 (2003).
77. Fossella F, Belani CP. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Cancer 104(12), 2766-2766 (2005).
78. Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J. Clin. Oncol. 24, 3657-3663 (2006).
79. Karampeazis L, Vamvakas A, Agelidou A et al. Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): a randomized Phase II Hellenic Oncology Research Group trial. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 7615).
80. Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized Phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 24(27), 4405-4411 (2006).
81. Tibaldi C, Bernardini I, Chella A et al. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin. Lung Cancer 7(6), 401-405 (2006).
82. Langer CJ, Vangel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc. Am. Soc. Clin. Oncol. 22, 639 (2003) (Abstract 2569).
83. Langer C, Li S, Schiller J et al. Randomized Phase II trial of paditaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J. Clin. Oncol. 25(4), 418-423 (2006).
84. Baka S, Ashcroft L, Anderson H et al. Randomized Phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤70) and advanced non-small-cell lung cancer. J. Clin. Oncol. 23(10), 2136-2144 (2005).
85. Leong SS, Toh CK, Lim WT et al. A randomized Phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/ or are elderly. J. Thorac. Oncol. 2(3), 230-236 (2007).
86. Lilenbaum R, Rubin M, Samuel J et al. A randomized Phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 2(4), 306-311 (2007).
87. Belani CP, Ramalingam S, Schreeder M et al. Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(Suppl. Pt I) 18S 7643 (2007).
88. Manegold C, Gatzemeier U, Buchholz E, Smith RP, Fandi A. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. Clin. Lung Cancer 6(6), 343-349, (2005).
89. Fandi A, Gatzemeier U, Smith R, Averbuch S, Manegold C. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc. Am. Soc. Clin. Oncol. 22, 655 (2003) (Abstract 2635).
90. Rixe O, Lemarie E, Chomy F et al. Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell-lung cancer (NSCLC): clinical results and biological monitoring. Proc. Am. Soc. Clin. Oncol. 22, 661 (2003) (Abstract 2659).
91. Fanucchi MP, Fossella FV, Belt R et al. Randomized Phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 24(31), 5025-5033 (2006).
92. Csiki I, Morrow JD, Sandler A et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a Phase II trial of celecoxib and docetaxel. Clin. Cancer Res. 11(18), 6634-6640 (2005).
93. Nugent FW, Mertens WC, Graziano S et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter Phase II trial. Lung Cancer 48(2), 267-273 (2005).
94. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol. 25(27), 4270-4277 (2007).
95. Fujino S, Asada Y, Nakano Y et al. A Phase II study of nedaplatin (CDGP) and docetaxel (TXT) in patients with advanced non-small cell lung cancer (NSCLC). J Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(Suppl. Pt1) 18S 7660 (2007).
96. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-ceff lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
97. William WN, Kies MS, Fossella FV et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J. Clin. Onco. 2007 ASCO Annual Meeting Proceedings 25(Suppl. Pt 1) 18S 18098 (2007).
98. Vansteenkiste J, Lara PN Jr, Le Chevalier T et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J. Clin. Oncol. 25(23), 3448-3455 (2007).
99. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitatel. Nanomed. 4, 415-423 (2007).
100. Laack E, Dierlamm. T, Knuffmann C et al. Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer 36(3), 309-311 (2002).
101. Rizvi NA, Riely GJ, Azzoti CG et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 26(4), 639-643 (2008).
102. Azzoli CG, Krug LM, Miller VA et al. A Phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J. Thorac. Oncol. 2(7), 638-644 (2007).
103. Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 92(8), 2158-2163 (2001).
104. Ardizzoia A, Acquati M, Fagnani D et al. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian Phase II study. Lung 182(1), 1-8 (2004).
105. Esteban E, Gonzalez de Sande L, Fernandez Y et al. Prospective randomised Phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann. Oncol. 14(11), 1640-1647 (2003).
106. Petrioli R, Pozzessere D, Messinese S et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 39(1), 85-89 (2003).
107. Serke M, Schoenfeld N, Loddenkemper R. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial. Anticancer Res. 24(2C), 1211-1216 (2004).
108. Rossi D, Graziano F, Ugolini M et al. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a Phase II study. Tumori 90(1), 50-53 (2004).
109. Vazquez S, Grande C, Amenedo M et al. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a Phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anticancer Drugs 15(5), 489-494 (2004).
110. Chen Y-M, Shih J-F, Tsai C-M, Perng R-P, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients failing previous chemotherapy. Chest 129(4), 840-842 (2006).
111. Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a Phase II study in Caucasian and Asian patients. Ann. Oncol. 14(3),449-454 (2003).
112. Georgoulias V, Androulakis N, Dimopoulos AM et al. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter Phase II study. Ann. Oncol. 9(3), 331-334 (1998).
113. Le Chevalier T, Monnier A, Douillard JY et al. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur. J. Cancer 34(13), 2032-2036 (1998).
114. Lee JJ, Han JY, Lee DH et al. A Phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. J. Clin. Pathol. 58(6), 650-654 (2005).
115. Raez LE, Santos ES, Lopes G et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer 53(3), 347-353 (2006).
116. Chen YM, Shih JF, Lee CS et al. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer 39(2), 209-214 (2003).
117. Yamamoto N, Fukuoka M, Negoro SI et al. Randomised Phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br. J. Cancer 90(1), 87-92 (2004).
118. Seto T, Takezako Y, Nakamura H et al. Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a Phase II study. Int. J. Clin. Oncol. 9(5), 378-382 (2004).
119. Grossi F, Fasola, G, Rossetto C et al. Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer 52(1), 89-92 (2006).
120. Leu KM, Kim KM, Larson M et al. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 34(1), 105-113 (2001).